Type IV Collagen in Hypertrophic Cardiomyopathy.
نویسندگان
چکیده
منابع مشابه
Myocardial collagen turnover in hypertrophic cardiomyopathy.
BACKGROUND Myocardial interstitial fibrosis is a characteristic of hypertrophic cardiomyopathy (HCM). This study evaluates the collagen turnover in HCM and its impact on left ventricular (LV) diastolic function. METHODS AND RESULTS Thirty-six HCM patients and 14 sex- and age-matched controls were studied. Collagen turnover was assessed as follows. By radioimmunoassay, a byproduct of collagen ...
متن کاملDIFFUSE CORONARY ARTERIAL ECTASIA WITH HYPERTROPHIC CARDIOMYOPATHY
A 40 year old male, a known case of hypertrophic cardiomyopathy, was admitted for catheterization. At catheterization and angiography, septum was hypertrophied to about 5cm and diffuse coronary artery aneurysm was revealed. We found no previous report of coronary artery aneurysm in hypertrophic cardiomyopathy.
متن کاملHyaluronan and Collagen in Human Hypertrophic Cardiomyopathy: A Morphological Analysis
Introduction. The hypertrophic cardiomyopathy (HCM) disease process is not only limited to cardiomyocyte abnormalities but also engages the extracellular matrix. Hyaluronan (HA) and its receptor CD44 are involved in cellular growth and tissue proliferation but have so far been less studied in myocardial hypertrophy. In HCM, collagens are abundant but their histological distribution and relation...
متن کاملPrognostic value of the collagen volume fraction in hypertrophic cardiomyopathy.
BACKGROUND In hypertrophic cardiomyopathy (HCM), interstitial myocardial fibrosis is an important histological modification that has been associated with sudden death and evolution toward myocardial dilation. OBJECTIVE To prospectively evaluate the prognostic value of the collagen volume fraction in HCM. METHODS An endomyocardial biopsy of the right ventricle was successfully performed in 2...
متن کاملValsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy.
BACKGROUND Fibrosis, as well as myocyte hypertrophy, is the major determinant of prognosis in hypertrophic cardiomyopathy (HCM). Valsartan, an angiotensin II type 1 receptor blocker, may improve myocardial fibrosis in patients with HCM. METHODS AND RESULTS Twenty-three patients with HCM were randomly divided into 2 groups: 11 patients had valsartan added to conventional treatment (V group) an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Heart Journal
سال: 1994
ISSN: 0021-4868,1348-673X
DOI: 10.1536/ihj.35.311